A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts

Acta Neuropathologica

Volumn 121, Issue 5, 2011, Pages 651-661

  Malley, Deborah S ^a   Hamoudi, Rifat A ^a   Kocialkowski, Sylvia ^a   Pearson, Danita M ^a   Collins, Vincent Peter ^a   Ichimura, Koichi ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Luciferase assay; Methylation; MGMT; Nucleosome positioning; Pyrosequencing; Temozolomide

Indexed keywords

LUCIFERASE; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; CPG ISLAND; ENZYME ACTIVITY; ENZYME ASSAY; GENE CONTROL; GENE DELETION; GENE EXPRESSION REGULATION; GENE SILENCING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; O6 METHYLGUANINE DNA METHYLTRANSFERASE GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN METHYLATION; PYROSEQUENCING; REGULATOR GENE; TRANSCRIPTION REGULATION; XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEINS;

EID: 79958165458     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-011-0803-5     Document Type: Article

References (36)

1. Bhakat KK, Mitra S (2003) CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration. Carcinogenesis 24:1337-1345 (Pubitemid 37038823)
2. Brada M, Stenning S, Gabe R et al (2010) Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 28:4601-4608
3. Chodavarapu RK, Feng S, Bernatavichute YV et al (2010) Relationship between nucleosome positioning and DNA methylation. Nature 466:388-392
4. Costello JF, Futscher BW, Kroes RA, Pieper RO (1994) Methylation-related chromatin structure is associated with exclusion of transcription factors from and suppressed expression of the O-6-methylguanine DNA methyltransferase gene in human glioma cell lines. Mol Cell Biol 14:6515-6521
5. de la Iglesia N, Puram SV, Bonni A (2009) STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med 9:580-590
6. Dunn J, Baborie A, Alam F et al (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101:124-131
7. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797 (Pubitemid 29086728)
8. Esteller M, Herman JG (2004) Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 23:1-8 (Pubitemid 38142234)
9. Everhard S, Tost J, El Abdalaoui H et al (2009) Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol 11:348-356
10. Fuxe J, Akusjarvi G, Goike HM, Roos G, Collins VP, Pettersson RF (2000) Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A. Cell Growth Differ 11:373-384 (Pubitemid 30619565)
11. Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296-307
12. Goike HM, Asplund AC, Pettersson EH, Liu L, Ichimura K, Collins VP (2000) Cryopreservation of viable human glioblastoma xenografts. Neuropathol Appl Neurobiol 26:172-176 (Pubitemid 30251390)
13. Harris LC, Potter PM, Tano K, Shiota S, Mitra S, Brent TP (1991) Characterization of the promoter region of the human O6-methylguanine-DNA methyltransferase gene. Nucleic Acids Res 19:6163-6167 (Pubitemid 21913034)
14. Harris LC, Remack JS, Brent TP (1994) Identification of a 59 bp enhancer located at the first exon/intron boundary of the human O6-methylguanine DNA methyltransferase gene. Nucleic Acids Res 22:4614-4619 (Pubitemid 24354791)
15. Harris LC, Remack JS, Brent TP (1994) In vitro methylation of the human O6-methylguanine-DNA methyltransferase promoter reduces transcription. Biochim Biophys Acta 1217:141-146
16. Hegi ME, Liu L, Herman JG et al (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189-4199
17. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826 (Pubitemid 26296693)
18. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP (2000) Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60:417-424 (Pubitemid 30070771)
19. Kaina B, Christmann M, Naumann S, Roos WP (2007) MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 6:1079-1099 (Pubitemid 47058389)
20. Kaplan N, Moore IK, Fondufe-Mittendorf Y et al (2009) The DNA-encoded nucleosome organization of a eukaryotic genome. Nature 458:362-366
21. Karayan-Tapon L, Quillien V, Guilhot J et al (2010) Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 97:311-322
22. Liu L, Backlund LM, Nilsson BR et al (2005) Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 83:917-926 (Pubitemid 41598692)
23. Mikeska T, Bock C, El-Maarri O et al (2007) Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9:368-381 (Pubitemid 47305073)
24. Nakagawachi T, Soejima H, Urano T et al (2003) Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 22:8835-8844 (Pubitemid 38021499)
25. Patel SA, Graunke DM, Pieper RO (1997) Aberrant silencing of the CpG island-containing human O6-methylguanine DNA methyltransferase gene is associated with the loss of nucleosome-like positioning. Mol Cell Biol 17:5813-5822 (Pubitemid 27411088)
26. Qian XC, Brent TP (1997) Methylation hot spots in the 5′ flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res 57:3672-3677 (Pubitemid 27381206)
27. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120:567-584
28. Sasai K, Nodagashira M, Nishihara H et al (2008) Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis. Am J Surg Pathol 32:1220-1227
29. Segal E, Widom J (2009) What controls nucleosome positions? Trends Genet 25:335-343
30. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
31. Tabatabai G, Stupp R, van den Bent MJ et al (2010) Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol 120:585-592
32. Tost J, El abdalaoui H, Gut IG (2006) Serial pyrosequencing for quantitative DNAmethylation analysis. Biotechniques 40:721-722, 724, 726
33. Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS, Futscher BW (1997) Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17:5612-5619 (Pubitemid 27357657)
34. Weller M, Felsberg J, Hartmann C et al (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27:5743-5750
35. Zeng N, Liu L, McCabe MG, Jones DT, Ichimura K, Collins VP (2009) Real-time quantitative polymerase chain reaction (qPCR) analysis with fluorescence resonance energy transfer (FRET) probes reveals differential expression of the four ERBB4 juxta-membrane region variants between medulloblastoma and pilocytic astrocytoma. Neuropathol Appl Neurobiol 35:353-366
36. Zhao W, Soejima H, Higashimoto K et al (2005) The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island. J Biochem 137:431-440 (Pubitemid 40628452)